The use of ICI to interfere with any single immunosuppressive mechanism employed by Treg, is therefore unlikely to allow sufficient re-engagement of CD8 T-cell effector activity, to result in impressive anti-tumor efficacy. The gene discussed is CD8A; the disease is neoplasm.